Study of the effect of cyclophosphamide and doxorubicin on the progress of pregnancy and histomorphological structure of the ovaries of white rats
DOI:
https://doi.org/10.63682/jns.v14i32S.8438Keywords:
cyclophosphamide, doxorubicin, pregnancy, stillbirth, ovariesAbstract
The article is devoted to the study of changes in the course of pregnancy and final outcomes against the background of the introduction of cyclophosphamide and doxorubicin to pregnant female white rats, as well as morphohistological changes developing in organs against the background of the introduction of cyclophosphamide and doxorubicin. The results of the studies showed that the duration of pregnancy in pregnant females receiving cyclophosphamide at a dose of 10 mg / kg decreased by 27.1% compared with the control group, the prenatal weight of animals decreased by 39.3% compared with the control group, and the postnatal weight decreased by 33.4%. The difference between prenatal and postnatal weight was 56.8%. The number of cubs decreased by 40.6%, and their weight by 43.9% compared with the number of cubs in the control group. When cyclophosphamide was prescribed at a dose of 20 mg / kg, the changes that occurred in the mother and offspring during pregnancy were more serious. In pregnant rats given doxorubicin at a dose of 2.5 mg/kg twice a week from the 8th day of pregnancy, the duration of pregnancy was 18.5% shorter compared to females in the control group, the prenatal weight of the animals decreased by 28.2% compared to the control group, and the postnatal weight by 29.9%. The difference between prenatal weight and postnatal weight was 25.4%. The number of pups also decreased by 29.8% compared to the number of pups in the control group. The birth weight of pups also decreased by 27.3% compared to the control group. These parameters decreased more significantly with the introduction of doxorubicin at a dose of 5 mg/kg. In pregnant rats given cyclophosphamide at a dose of 10 mg/kg and doxorubicin at a dose of 2.5 mg/kg from the 8th day of pregnancy for 1 week, the duration of pregnancy was reduced by 50.5%. The prenatal weight of the animals decreased by 50.2% compared to the control group, and the postnatal weight by 47.7%. The difference in prenatal and postnatal weight was 57.6%. A decrease in the number of pups by 90.1% was noted. The weight of the pups at birth also decreased by 50.7%. Against the background of the combined administration of cyclophosphamide at a dose of 20 mg/kg and doxorubicin at a dose of 5 mg/kg, the pregnancy did not end normally, and since the birth of cubs was not observed, the number of cubs was not determined, and since cubs were not born, it was not possible to determine their weight. When studying the histomorphological changes developing in the ovaries against the background of the administration of cytostatics to female rats for a week, it was shown that destructive changes, leukocyte infiltration and cellular edema are observed in the organs
Downloads
References
Cancer Facts & Figures 2017 [Electronic resource] // American Cancer Society. – Mode of access: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017 (accessed: 02.25.2018).
.Eskander R.N., Kurzrock R. Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies. Med. 2021; 2 (3): 1–5.
. Miraslanov Hliman, Qazıyev Abuzər, İbrahimov Hbəkbər Oncology Gynecology, Monotherapy, Cancer Research and Politics, Baku 2024, 1104 pages, p. 81-133.
. Oncology. Textbook Edited by Sh.Kh. Gancev GEOTAR-Media, 2023 Hardcover, 704 pages
. Vladimirova L.Yu., Gladkov O.A., Koroleva I.A. et al. Practical recommendations for the prevention and treatment of nausea and vomiting in cancer patients. Malignant tumors. 2021;11(3s2-2):25-38. https://doi.org/10.18027/2224-5057-2021-11-3s2-37.
. Kedrova A.G., Levakov S.A. Oncological diseases in pregnant women. Modern tactics and main difficulties. Clinical practice. 2014. No. 3. P. 43-50.
. Pauker V. Oncological diseases and pregnancy. Oncogynecology 2014. No. 4. P. 59-67.
. Volochaeva M.V., Shmakov R.G., Demina E.A. The influence of antitumor treatment on the reproductive system of women: methods of protection and preservation of ovarian function // Clinical oncohematology. 2014. Vol. 7. No. 2. P. 114-121.
. Salov I.A., Basova T.A., Mikhailova Yu.V., Frolova Ya.I. Pregnancy-associated breast cancer: features of the course, diagnosis and treatment. Obstetrics, Gynecology, Reproductology, 2024, Vol. 18, No. 5, P.754-760.
. Yasenko D.M., Shelkovich S.E. Pregnancy-associated breast cancer. Innovations in Medicine and Pharmaceutics-2018: collection of materials from the distance scientific and practical conference of students and young scientists. Minsk, 2018. 531-33.
. Garcia, M.R. The impact of aging on innate and adaptive immunity in the human female genital tract / M.R. Garcia, M.V. Patel, Z. Shen, C.R. Wira // Aging Cell. -2021. - Vol.20, No.5. - P. 13361.
.Nguyen Q.N., Zerafa N., Liew S.H., Findlay J.K., Hickey M., Hutt K.J. Csplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes. Mol. Hum. Reprod. 2019; 25(8): 433-44. https://dx.doi.org/10.1093/molehr/gaz020.
. Asanov M.A., Poddubnyak A.O., Mukhamadiyarov R.A., Sinitskaya A.V., Khutornaya M.V., Sinitsky M.Yu. Comprehensive assessment of subchronic low-dose doxorubicin exposure in Wistar rats. Siberian Journal of Clinical and Experimental Medicine. 2024;39(4):171-179. https://doi.org/10.29001/2073-8552-2024-39-4-171-179
. Liu W, Chen W, Zhang X, Zhao P, Fan Z, Bi L, et al. Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin. Sci Rep. 2021 Jan 8;11(1):199. https://doi.org/10.1038/s41598-020-80415-w
. Balykova LA, Inchina VI, Tarasova TV, Mosina LM, Gvozdikova EN, Khaidar DA, Myandina GI, Ryzhakin SM, Saushev IV. Efficiency of liposomal doxorubicin hydrochloride in combination with cyclophosphamide in the treatment of breast cancer in an experiment. Research and practice in medicine. 2021; 8(4): 23-32. https://doi.org/10.17709/2410-1893-2021-8-4-2.
. Volochaeva M.V., Shmakov R.G., Demina E.A. The influence of antitumor treatment on the reproductive system of women: methods of protection and preservation of ovarian function // Clinical oncohematology. 2014. Vol. 7. No. 2. P. 114-121. 17.Əmiraslanov Əhliman, Qazıyev Abuzər, İbrahimov Əkbər Yumurtalıqların Bədxassəli Şişləri, Dərs vəsaiti, Şərq-Qərb ASC Nəşriyyat və Poliqrafiya, Bakı 2023, 236 səhifə, p.102-103
. Ghignatti PV da C, Nogueira LJ, Lehnen AM, Leguisamo NM. Cardioprotective effects of exercise training on doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis of preclinical studies. Sci Rep. 2021 Mar 18;11(1):6330. https://doi.org/10.1038/s41598-021-83877-8
. Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes. St. Petersburg, 2012. 48 p.
. Lapin K.N., Ryzhkov I.A., Zakharova N.M. The effect of cyclophosphamide on the reproductive system of male rats // Experimental and clinical pharmacology. 2020. Vol. 83. No. 11. Pp. 16-19.
. Clinical guidelines - Breast cancer - 2021-2022-2023 (20.01.2023). Moscow: Ministry of Health of the Russian Federation, 2023. 94 p. Access mode: http://disuria.ru/_ld/12/1279_kr21D05C50MZ.pdf. [Accessed: 30.08.2024]. 22. Andreev D.A., Balakin E.I., Samoilov A.S., Pustovoit V.I. The role of doxorubicin in the formation of cardiotoxicity is a generally accepted statement. Part I. Prevalence and mechanisms of formation (review). Development and registration of drugs. 2024; 13 (1): 190-199. https://doi.org/10.33380/2305-2066-2024-13-1-1508
. Balykova L. A., Inchina V. I., Tarasova T. V., Mosina L. M., Gvozdikova E. N., Khaidar D. A., M
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.